María Victoria
Mateos Manteca
VU University Medical Center
Ámsterdam, HolandaPublicaciones en colaboración con investigadores/as de VU University Medical Center (20)
2023
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
2020
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2018
-
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Critical Reviews in Oncology/Hematology, Vol. 121, pp. 74-89
-
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial
Journal of Clinical Oncology
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology, Vol. 28, pp. iv52-iv61
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
-
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network
Leukemia, Vol. 2017
2016
-
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Blood, Vol. 127, Núm. 6, pp. 681-695
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Drugs, Vol. 76, Núm. 8, pp. 853-867
-
Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group
Blood, Vol. 127, Núm. 24, pp. 2955-2962
2015
-
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report
Blood, Vol. 125, Núm. 13, pp. 2068-2074
2014
-
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Leukemia, Vol. 28, Núm. 8, pp. 1573-1585
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
2013
-
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
Haematologica, Vol. 98, Núm. 6, pp. 980-987
2011
-
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Blood, Vol. 118, Núm. 17, pp. 4519-4529